(Q37810508)

23 August 2017

title

Imatinib and the treatment of fibrosis: recent trials and tribulations (English)

1 reference

23 August 2017

1 reference

Jessica Gordon

1

1 reference

23 August 2017

Robert Spiera

series ordinal

2

1 reference

23 August 2017

publication date

1 February 2011

1 reference

Current Rheumatology Reports

23 August 2017

published in

1 reference

23 August 2017

volume

13

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

51-58

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-010-0146-6

23 August 2017

exact match

0 references

cites work

Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-010-0146-6

Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-010-0146-6

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-010-0146-6

Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension

21 January 2018

1 reference

12 December 2020

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

1 reference

12 December 2020

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model

1 reference

12 December 2020

Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis

1 reference

12 December 2020

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

1 reference

12 December 2020

Smad transcription factors

1 reference

12 December 2020

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

1 reference

12 December 2020

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

1 reference

12 December 2020

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

1 reference

12 December 2020

Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.

1 reference

12 December 2020

Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma

1 reference

12 December 2020

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

1 reference

12 December 2020

A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.

1 reference

12 December 2020

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

12 December 2020

A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate

1 reference

12 December 2020

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

1 reference

12 December 2020

Systemic sclerosis: a prototypic multisystem fibrotic disorder

1 reference

12 December 2020

MicroRNA-29, a key regulator of collagen expression in systemic sclerosis

1 reference

12 December 2020

Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study.

1 reference

12 December 2020

Imatinib for the treatment of refractory, diffuse systemic sclerosis

1 reference

12 December 2020

Imatinib mesylate treatment of nephrogenic systemic fibrosis

1 reference

12 December 2020

Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology

1 reference

12 December 2020

PDGF signaling in pulmonary arterial hypertension

1 reference

12 December 2020

Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts

1 reference

12 December 2020

Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).

1 reference

12 December 2020

Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate

1 reference

12 December 2020

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

1 reference

12 December 2020

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials

1 reference

12 December 2020

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

1 reference

12 December 2020

Congestive heart failure is a rare event in patients receiving imatinib therapy

1 reference

12 December 2020

Disease-modifying treatment in systemic sclerosis: current status.

1 reference

12 December 2020

Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being

1 reference

12 December 2020

Molecular framework for response to imatinib mesylate in systemic sclerosis.

1 reference

12 December 2020

Fibrosis in systemic sclerosis

1 reference

12 December 2020

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

1 reference

12 December 2020

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

1 reference

12 December 2020

Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.

1 reference

12 December 2020

Is imatinib mesylate a promising drug in systemic sclerosis?

1 reference

12 December 2020

Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease

1 reference

12 December 2020

Increased expression of platelet-derived growth factor type b receptors in the skin of patients with systemic sclerosis

1 reference

12 December 2020

Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon

1 reference

12 December 2020

Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis

1 reference

12 December 2020

10.1007/S11926-010-0146-6

Identifiers

DOI

1 reference

23 August 2017

1 reference